Kenneth Marek, MD
President and Senior Scientist at The Institute for Neurodegenerative Disorders
Kenneth Marek is president and senior scientist at the Institute for Neurodegenerative Disorders. Dr. Marek's major research interests include identification of biomarkers for early detection, assessment of disease progression and development of new treatments for Parkinson's disease and Alzheimer's disease and related neurodegenerative disorders. His specific interest has been in in vivo neuroreceptor imaging biomarkers. He has authored numerous neurology and neuroscience publications on these topics. Dr. Marek has and continues to be the principal investigator of several ongoing multi-center international studies (including the Parkinsonís Progression Markers Initiative [PPMI] and the Parkinson Associated Risk Syndrome [PARS] study).
Dr. Marek serves on the scientific advisory board of The Michael J. Fox Foundation. He has served on the executive committee of the Parkinson's Study Group and in leadership roles in the Huntington Study group. He also was a co-founder and continues to lead Molecular NeuroImaging, LLC, a company providing clinical neuroimaging research services.
- Radioactive Molecules for Detection of Alpha-synuclein and Amyloid-beta in the Brain (2017)
- Bay Area Solvent Study - Symptoms (BASS-S) (2012)
- DAT Imaging in Unaffected LRRK2 Gene Positive Subjects in a Chinese Community Cohort (2011)
- Clinical Assessment of Patients with PD Who Underwent DAT Scan and FDG PET at the Early Stages of Their Extra-Pyramidal Disorder as Part of Their Initial Workup (2010)
- The Parkinson's Progression Markers Initiative (PPMI) (2010)
- Assessing Heart Rate Variability (HRV) in the Parkinson's Associated Risk Study (PARS) Cohort (2009)
- DAT Imaging in Ashkenazi Jews (AJ) LRRK2 Gene Carriers - a consortium proposal (2009)
- A Strategy to Develop a Radiotracer Targeting Alpha-Synuclein (2009)
- Non-dopaminergic imaging biomarkers as tools for early PD - testing the Braak Hypothesis (2006)